CONTENTS

SI.NO. DESCRIPTION PAGE NO.

1. Introduction of tour 1

2. Tour 1

3. Visit to cipla 3

a) Introduction 3

b) Goa plant 4

c) History 5

d) Medicines & Product 6

e) Research and Development 10

f) Global Presence 11

4. Visit to Lupin 13

a) Introduction 13

b) Goa Plant 14

c) Medicines & Product 14

d) API (Active Pharmaceutical Ingredient) 17

e) Finished Product 17

f) Herbal Product 18

g) Research and development 19

Generics 19

New chemical entities 20

RANBAXY LABORATORY LIMITED 1 | P a g e

Novel Drug delivery systems 21

INTRODUCTION

According to R.G.P.V. syllabus for VIth Semester (IIIrd year) B. Pharmacy Students an

educational study tour to visit important manufacturing organization is compulsory. All

students will have to submit a tour report after the study tour. The marks shall be awarded

by the teacher in-charge of the students study tour. Every candidate shall be required to

submit the project tour report. .

TOUR

We visited MALNPUR industrial area Bhind (m.p.) for the industrial tour as

given in the syllabus. After our visit to Malnpur , we further visited to :

1.RANBAXY Labs ltd. Malanpur, it is located on the following address:

Factory/plant K-5,6,7 Ghirongi Malanpur Bhind District - 477116Madhya Pradesh – India

RANBAXY LABORATORY LIMITED 2 | P a g e

RANBAXY LABORATORY LIMITED 3 | P a g e

VISIT TO RANBAXY LABS LTD.

An introduction to Ranbaxy in India

Ranbaxy is one of the leading pharma Companies in India commanding a market share of 5.07%.

(Source : ORG-IMS, March, 2007). The Company has clocked sales of USD 286 Mn (2006)

registering a growth of over 17%. Growing ahead of the market the Company has enhanced its

competitive position in the domestic market through its focused approach. The Company’s

business has been realigned to its customer groups and investments have been made in high

growth segments. These efforts have resulted in strengthening its Chronic franchise (Life Style

led) as well as has reinforced its leading position in the Acute segment.

In the NDDS segment, Ranbaxy is the market leader with 7.9% market share and its NDDS

product portfolio contributes to about 9% of its total turnover. Its product portfolio spans across

Acute & Chronic Business covering Anti-infectives, Nutritionals, Gastro-intestinals, Pain

Management ( Acute) Cardiovasculars, Dermatologicals, Central Nervous Systems

(Chronic)segments.

Company’s India operations are a dominant force in a number of participating therapeutic

segments, for example Anti-infectives, Statins, Dermatology and Pain Management Operations

are structured into 9 Strategic Business Units. A publicly listed company, Ranbaxy India is also a

member of IPA (Indian Pharmaceutical Alliance) & OPPI (Organization of Pharmaceutical

Producers of India).

Amongst the pharmaceutical companies in India, Ranbaxy has the largest R&D budget with an

R&D spend of over US $ 100Mn

RANBAXY LABORATORY LIMITED 4 | P a g e

Ranbaxy views its R&D capabilities as a vital component of its business strategy that will

provide the company with a sustainable, long-term competitive advantage. The company today

has a pool of 1,200 scientists who are engaged in path-breaking research.

The robust R&D environment within the company for both drug discovery & development and

for generics is designed to bring into sharper focus, the unique needs of both equally. Ranbaxy's

endeavour is to be a leader in the generics space and also to build a strong proprietary

prescriptions business based on the Company's NDDS and NCE (New Chemical Entity) research

outcomes.

RANBAXY LABORATORY LIMITED 5 | P a g e

Manjeet Yadav Sinha

PH PHOTOGRAPH IN CIPLA

PHOTOGRAPH IN LUPIN

RANBAXY LABORATORY LIMITED 6 | P a g e

Manjeet Yadav